Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) FCF Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed FCF Margin for 5 consecutive years, with 53.11% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin changed N/A to 53.11% in Q4 2025 year-over-year; TTM through Dec 2025 was 30.19%, a N/A change, with the full-year FY2025 number at 24.58%, down 2988754.0% from a year prior.
  • FCF Margin was 53.11% for Q4 2025 at Soleno Therapeutics, down from 65.83% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 2406.83% in Q1 2025 to a low of 53.11% in Q4 2025.